XCUR

Exicure is no longer an operating drug company — it halted all R&D in 2022, sold its historical IP to Flashpoint Therapeutics, and now describes itself as a vehicle 'exploring strategic alternatives.' The FY2025 numbers confirm the emptiness: $0 revenue (down 100% after a token $500K license fee in FY2024), a cumulative deficit of $204M, and just $3.75M of cash against $8.55M of annual operating cash burn. Management states outright that 'our current liquidity may not be sufficient to fund operations for the next 12 months' — a going-concern flag. With 6.37M shares at $1.91 the market cap is ~$12M against $3.93M of book equity (~3x book), so you are paying up for a hollow balance sheet whose equity fell 42% in a year and whose liabilities/equity ratio is 2.58x.

The only 'story' is optionality: the January 2025 GPCR / GPCR USA acquisition and License & Collaboration Agreement, whose GPC-100 asset completed a Phase 2 blood-cancer trial in January 2026. But the terms load Exicure with milestone and royalty obligations — including a $1.0M milestone due in Q2 2026 payable in stock — and the company admits it must raise 'substantial funding' just to keep the lights on. Given ~$8.5M annual burn versus $3.75M cash, dilution is not a risk, it is a certainty, and it will come on whatever terms are available to a distressed micro-cap.